SAN DIEGO, Jun 23, 2008 (BUSINESS WIRE) -- Illumina, Inc. (NASDAQ:ILMN) today announced the appointment of
Fredrick Clerie as Vice President of Quality Assurance and Regulatory
Affairs reporting to Joel McComb, Senior Vice President and General
Manager of Illumina's Life Sciences Business Unit. In this newly
created role, Fredrick will be responsible for managing and enhancing
Illumina's comprehensive Quality systems strategy to support the
development, manufacture, and distribution of products serving the
research and molecular diagnostic markets.

Prior to joining Illumina, Fredrick served as Vice President of
Global Quality Assurance and Regulatory Affairs for the Diagnostics
Division of Bayer HealthCare, now Siemens Diagnostics. Under
Fredrick's leadership, Bayer HealthCare's Diagnostics Division
successfully obtained Premarket Approvals (PMA) for five automated
infectious disease assays. Fredrick's previous role was Vice President
of Quality Assurance for the Laboratory Testing Segment (LTS) of Bayer
HealthCare. During his three years at LTS, Fredrick successfully
managed 13 Food and Drug Administration (FDA) inspections, the
majority of which concluded with no report of any observation or
non-conformance. He also served as the lead representative in direct
negotiations with the FDA's Center for Devices and Radiological Health
(CDRH), which resulted in shortened PMA review periods for hepatitis
assays.

From 1992 to 2001 Fredrick held multiple positions at Bayer
Diagnostics, most notably as Director of Regulatory Affairs. In this
role, Fredrick was responsible for the global expansion of the
Regulatory Affairs function. He also led pre-PMA meetings with both
the Center for Biologics Evaluation and Research and the CDRH related
to Bayer's commercialization initiative for automated hepatitis and
HIV assays. Prior to this role, Fredrick was Director of Business
Development, where he played a key role in negotiating alliances with
partners worldwide, and identified potential alliances that enhanced
the performance of both the Chemistry and Immunodiagnostics Business
Units for Bayer Healthcare.

Fredrick earned a B.A. in Biology and Chemistry from Greenville
College and a M.S. in Biochemistry from the University of Illinois.

"Fredrick brings to Illumina a wealth of knowledge in the field of
Quality Assurance and Regulatory Affairs," said Joel McComb. "His
diverse career history and experience with rapidly commercializing new
technologies will help us prepare for entering the molecular
diagnostics market."

About Mr. Clerie's Compensation

The Company granted an option to purchase 56,000 shares of
Illumina's common stock to Mr. Clerie as part of his inducement to
join the company. The option was granted by the Company's compensation
committee pursuant to NASDAQ Marketplace Rule 4350(i)(1)(A)(iv) and
under Illumina's New Hire Stock and Incentive Plan, which was approved
by Illumina's Board of Directors on January 29, 2008. This option has
the following terms: an exercise price equal to the closing fair
market value of Illumina's common stock on the grant date, a ten-year
term and vesting over four years with 25 percent of the option vesting
one year from the grant date and 1/48th of the option vesting monthly
thereafter. The grant date for this option is June 23, 2008.

About Illumina

Illumina (www.illumina.com) is a leading developer, manufacturer,
and marketer of next-generation life-science tools and integrated
systems for the large-scale analysis of genetic variation and
biological function. Using our proprietary technologies, we provide a
comprehensive line of products and services that currently serve the
sequencing, genotyping, and gene expression markets, and we expect to
enter the market for molecular diagnostics. Our customers include
leading genomic research centers, pharmaceutical companies, academic
institutions, clinical research organizations, and biotechnology
companies. Our tools provide researchers around the world with the
performance, throughput, cost effectiveness, and flexibility necessary
to perform the billions of genetic tests needed to extract valuable
medical information from advances in genomics and proteomics. We
believe this information will enable researchers to correlate genetic
variation and biological function, which will enhance drug discovery
and clinical research, allow diseases to be detected earlier, and
permit better choices of drugs for individual patients.

"Safe Harbor" Statement under the Private Securities Litigation
Reform Act of 1995: this release may contain forward-looking
statements that involve risks and uncertainties. Among the important
factors that could cause actual results to differ materially from
those in any forward-looking statements are Illumina's ability (i) to
integrate effectively our recent acquisition of Solexa, Inc., (ii) to
develop and commercialize further our BeadArray(TM), VeraCode(R), and
Solexa(R) technologies and to deploy new sequencing, gene expression,
and genotyping products and applications for our technology platforms,
(iii) to manufacture robust microarrays and Oligator(R)
oligonucleotides, (iv) to integrate and scale our VeraCode technology,
together with other factors detailed in our filings with the
Securities and Exchange Commission including our recent filings on
Forms 10-K and 10-Q or in information disclosed in public conference
calls, the date and time of which are released beforehand. We disclaim
any intent or obligation to update these forward-looking statements
beyond the date of this release.

SOURCE: Illumina, Inc.

Illumina, Inc.
Media:
Maurissa Bornstein, Public Relations Manager
858-332-4055
mbornstein@illumina.com
or
Investors:
Peter J. Fromen, Sr. Director, Investor Relations
858-202-4507
pfromen@illumina.com

Copyright Business Wire 2008